Key Highlights

  • Beta Bionics reported third quarter net sales of USD 35.5 million, up 30% year over year and roughly in line with estimates.
  • The company posted a net loss of USD 24.4 million, or USD 0.52 per share, compared with a smaller loss a year earlier.
  • Gross margin reached 57.3%, up 179 basis points year over year, despite a sequential decline tied to channel mix.
  • Beta Bionics raised its full year 2026 revenue guidance to a range of USD 124 million to USD 126 million.

Record Revenue Follows FDA Clearance of New Device

Beta Bionics (NASDAQ:BBNX) reported third quarter net sales of USD 35.5 million, up approximately 30% year over year, driven by new patient starts and an expanding user base in the pharmacy reimbursement channel. The quarter followed the company's September FDA clearance of its Mint patch pump, which the company expects to commercialize in the United States beginning in the first quarter of 2027.

The company completed a public offering in September, raising approximately USD 161 million in net proceeds to support the Mint commercialization effort and broader operations. Durable Medical Equipment channel revenue grew 4% year over year to USD 21.9 million, while pharmacy benefit plan revenue rose 46% to USD 46.9 million, reflecting increased sales force investment.

Margin Trends and Updated Full Year Guidance

Gross margin was 57.3% for the quarter, up 179 basis points from a year earlier, though it declined 178 basis points sequentially due to an unfavorable revenue mix within the Durable Medical Equipment channel. The net loss widened to USD 24.4 million, or USD 0.52 per share, from USD 14.2 million in the prior year period, while adjusted EBITDA was negative USD 18.9 million, compared with negative USD 12.2 million a year earlier.

The company raised its full year 2026 revenue guidance to a range of USD 124 million to USD 126 million, up from a prior range of USD 121 million to USD 126 million. Full year gross margin guidance was set at 58.5% to 59.5%, assuming the revenue mix normalizes in the fourth quarter.

Fourth Quarter Transition and Regulatory Considerations

Fourth quarter revenue guidance of USD 29 million to USD 31 million incorporates a projected deferral of up to USD 8.5 million as some prospective patients wait for the Mint launch rather than purchasing current generation devices. The company separately withdrew its 510(k) submission for a new algorithm feature after regulators requested additional validation data, a step that could affect the timing of that feature's availability.

Continued strong multiple daily injection conversion rates, which accounted for 69% of new patient starts in the quarter, could support demand once Mint reaches the market, while any further delay in the Mint launch or additional regulatory requests could extend the revenue deferral effect into subsequent quarters.

What to Watch Into the Mint Launch

The commercial launch of Mint in the first quarter of 2027, the resolution of the 3D Intelligence algorithm's regulatory review, and the pace of insurance coverage expansion, which the company expects to reach about 40% of lives at launch, are among the items the company has flagged for investors. Fourth quarter revenue relative to the guided deferral range is a specific data point the company has called out ahead of the launch.